Veröffentlichungen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Bunse, Mario Dr. (1) Kammertöns, Thomas Dr. (3) Kettenmann, Helmut Prof. Dr. (1) Lorenz, Felix Dr. (3) Obenaus, Matthias (1) Poncette, Lucia (1) Uckert, Wolfgang Prof. Dr. (22) (-) Blankenstein, Thomas Prof. Dr. (7) (-) Gavvovidis, Ioannis Dr. (1) (-) Leisegang, Matthias Dr. (5) (-) Rhein, Simone Dr. (2) Bioinformatics (1) Biologie maligner Lymphome (17) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Immunregulation und Krebs (1) Mikroumgebung als Regulator bei Autoimmunität und Krebs (1) Molekulare Immunologie und Gentherapie (22) Molekulare Immuntherapie (4) (-) Molekulare Zellbiologie und Gentherapie (11) Proteom Dynamik (2) RNA Biologie und Posttranscriptionale Regulation (1) Signaltransduktion in Tumorzellen (2) Strukturbiologie Membran-assoziierter Prozesse (1) Systembiologie von Gen-regulatorischen Elementen (4) Zelldifferenzierung und Tumorigenese (1) Zellzustände und ihre Funktionsweisen (1) 1998 (2) 2000 (2) 2003 (4) 2004 (1) 2005 (3) 2006 (2) (-) 2007 (2) 2008 (2) 2010 (4) (-) 2011 (2) 2012 (3) (-) 2014 (3) (-) 2015 (3) 2016 (2) 2017 (2) (-) 2019 (1) 11 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Gavvovidis, Ioannis Dr.Leisegang, Matthias Dr.Rhein, Simone Dr.Molekulare Zellbiologie und Gentherapie20072011201420152019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein 01. Juni 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert 01. April 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber 01. April 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein 01. Dezember 2014 in Hum Gene Ther Clin Dev HEK293-based production platform for γ-retroviral (SIN-) vectors: application for safe and efficient transfer of COL7A1 cDNA K. Hennig L. Raasch C. Kolbe S. Weidner M. Leisegang W. Uckert M. Titeux A. Hovnanian K. Kuehlcke R. Loew 01. September 2014 in Eur J Immunol Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells S. Pinto D. Sommermeyer C. Michel S. Wilde D. Schendel W. Uckert T. Blankenstein B. Kyewski 01. Januar 2014 in Eur J Immunol TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs S. Reuß Z. Sebestyén N. Heinz R. Loew C. Baum R. Debets W. Uckert 28. Juli 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 15. Januar 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 15. Oktober 2007 in J Immunol Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity M. Weinhold D. Sommermeyer W. Uckert T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
01. Juni 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert
01. April 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
01. April 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
01. Dezember 2014 in Hum Gene Ther Clin Dev HEK293-based production platform for γ-retroviral (SIN-) vectors: application for safe and efficient transfer of COL7A1 cDNA K. Hennig L. Raasch C. Kolbe S. Weidner M. Leisegang W. Uckert M. Titeux A. Hovnanian K. Kuehlcke R. Loew
01. September 2014 in Eur J Immunol Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells S. Pinto D. Sommermeyer C. Michel S. Wilde D. Schendel W. Uckert T. Blankenstein B. Kyewski
01. Januar 2014 in Eur J Immunol TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs S. Reuß Z. Sebestyén N. Heinz R. Loew C. Baum R. Debets W. Uckert
28. Juli 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
15. Januar 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
15. Oktober 2007 in J Immunol Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity M. Weinhold D. Sommermeyer W. Uckert T. Blankenstein
